Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Mapping the MHC class I spliced immunopeptidome of cancer cells.


Liepe,  J.
Research Group of Quantitative and System Biology, MPI for Biophysical Chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Liepe, J., Sidney, J., Lorenz, F. K. M., Sette, A., & Mishto, M. (2019). Mapping the MHC class I spliced immunopeptidome of cancer cells. Cancer Immunology Research, 7(1), 62-76. doi:10.1158/2326-6066.CIR-18-0424.

Cite as: http://hdl.handle.net/21.11116/0000-0002-7DFD-6
Anti-cancer immunotherapies demand optimal epitope targets, which could include proteasome-generated spliced peptides if tumor cells were to present them. Here, we show that spliced peptides are widely presented by MHC class I molecules of colon and breast carcinoma cell lines. The peptides derive from hot spots within antigens and enlarge the antigen coverage. Spliced peptides also represent a large number of antigens that would otherwise be neglected by patrolling T cells. These antigens tend to be long, hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an enlarged pool of antigens associated with cancer.